This $880,735 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Washington to investigate the mechanisms behind the induction of type 2 immunity in the lung. The research aims to uncover how loss of plasma membrane integrity coordinates the release of IL-33 and leukotriene C4 (LTC4) as a unifying mechanism for triggering type 2 immunity, which is involved in diseases like asthma. Key aspects include identifying alveolar macrophages as a source of LTC4 and examining the roles of LTC4 and its metabolite LTD4 in acute and long-term innate type 2 immunity in the lung. The award period runs from February 1, 2025 through November 30, 2028.
Generated 3/4/25, 6:24 AM